

**Amendments to the Claims:**

Please add claim 40 as presented below.

The listing of claims will replace all prior version, and listings, of claims in the application:

**Listing of Claims:**

Claims 1 to 18 (Canceled)

19. (Previously Presented) An antibody that binds to a substantially pure fibroblast growth factor homologous factor-4 (FHF-4) polypeptide.

20. (Original) The antibody of claim 19, wherein the antibody is monoclonal.

21. (Withdrawn) A method of detecting a cell proliferative disorder associated with expression of a fibroblast growth factor homologous factor-4 (FHF-4) polypeptide, the method comprising the steps of:

- a. contacting a specimen from a subject having or suspected of having the disorder with a reagent that detects expression of the FHF-4 polypeptide; and
- b. detecting binding of the reagent to the specimen.

22. (Withdrawn) The method of claim 21, wherein the cell is a brain cell.

23. (Withdrawn) The method of claim 21, wherein the reagent is an antibody.

24. (Withdrawn) The method of claim 21, wherein the reagent is a nucleic acid.

25. (Withdrawn) The method of claim 24, wherein the nucleic acid hybridizes to a nucleic acid encoding the FHF-4 polypeptide.

26. (Withdrawn) The method of claim 24, wherein the nucleic acid hybridizes to the complement of a nucleic acid encoding the FHF-4 polypeptide.

27. (Withdrawn) The method of claim 21, wherein the detecting is carried out *in vivo*.
28. (Withdrawn) The method of claim 21, wherein the detecting is carried out *in vitro*.
29. (Withdrawn) The method of claim 21, wherein the reagent comprises a detectable label.
30. (Withdrawn) A method of treating a cell proliferative disorder associated with expression of a fibroblast growth factor homologous factor-4 (FHF-4) polypeptide, the method comprising administering to a subject having or suspected of having the disorder a reagent that suppresses the activity of the FHF polypeptide.
31. (Withdrawn) The method of claim 30, wherein the reagent is an anti-FHF-4 antibody.
32. (Withdrawn) The method of claim 30, wherein the reagent is a nucleic acid that hybridizes to a nucleic acid encoding the FHF-4 polypeptide.
33. (Withdrawn) The method of claim 30, wherein the cell is a brain cell.
34. (Withdrawn) The method of claim 30, wherein the reagent is introduced into the cell using a carrier.
35. (Withdrawn) The method of claim 34, wherein the carrier is a vector.
36. (Withdrawn) A method of identifying a nucleic acid encoding a fibroblast growth factor homologous factor-4 (FHF-4) polypeptide, the method comprising probing a sample containing a nucleic acid encoding the FHF-4 polypeptide with an FHF-4-specific nucleic acid probe.

37. (Withdrawn) The method of claim 36, wherein the FHF-4-specific nucleic acid probe hybridizes to:

- a. a nucleic acid that encodes seven consecutive amino acids, at least four of which are conserved in the amino acid sequence of FHF-4 (SEQ ID NO:4); or
- b. the complementary sequence thereto.

38. (Previously Presented) The antibody of claim 19, wherein FHF-4 polypeptide

- a. is about 225-250 amino acids in length;
- b. lacks an amino terminal signal sequence; and
- c. contains a nuclear localization signal.

39. (Previously Presented) The antibody of claim 19, wherein the FHF-4 polypeptide comprises a segment of at least five consecutive amino acids that are conserved in the amino acid sequence of FHF-4 (SEQ ID NO:4).

40. (New) The antibody of claim 19 having an antigen binding fragment that is a Fab fragment or an F(ab')<sub>2</sub> fragment.